Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population

التفاصيل البيبلوغرافية
العنوان: Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population
المؤلفون: Zhu, Roger C, Rattanakorn, Kirk, Pham, Steven, Mallam, Divya, McIntyre, Thomas, Salifu, Moro O, Youssef, Irini, McFarlane, Samy I, Vignesh, Shivakumar
المصدر: Colorectal Cancer; June 2017, Vol. 6 Issue: 1 p33-41, 9p
مستخلص: We assessed the association of metformin use with survival in colorectal cancer in a population consists mostly of African-American and Afro-Caribbean patients. We identified 585 colorectal cancer patients, 167 (28.6%) and 418 (71.5%) were as diabetic (DM) and nondiabetic, respectively. The diagnosis of diabetes did not impact cancer survival or extent of disease. Overall, DMs with metformin use (D+M+) have better overall survival than both DMs without metformin use (D+M∼) and nondiabetics (D∼M∼), with a mean survival of 109.9 months compared with 95.7 and 106.1 months, respectively (log-rank p < 0.05). The use of metformin shows significant reduction of risk of mortality compared with nonusers (hazard ratio: 0.34; 95% CI: 0.15–0.81; p = 0.01). Use of insulin and status of diabetes did not have a significant impact on overall cancer survival.
قاعدة البيانات: Supplemental Index
الوصف
تدمد:1758194X
17581958
DOI:10.2217/crc-2017-0001